Biopharma Deal Benchmarks by Therapeutic Area
Explore licensing, acquisition, and collaboration deal terms across 12 therapeutic areas, powered by 1,600+ verified transactions with disclosed financial terms.
Oncology
Most active TA for deal volume
View deal benchmarks →
Neurology & CNS
#1 in total deal value in 2026
View deal benchmarks →
Immunology
$13B+ in verified deal value
View deal benchmarks →
Cardiovascular
Novel mechanisms driving revival
View deal benchmarks →
Metabolic & Obesity
GLP-1 licensing race heats up
View deal benchmarks →
Rare Disease
15-25% PoS vs 7-12% overall
View deal benchmarks →
Infectious Disease
Post-pandemic platform deals
View deal benchmarks →
Ophthalmology
Premium retinal deal valuations
View deal benchmarks →
Dermatology
AD & psoriasis biologics boom
View deal benchmarks →
Women's Health
Underserved market, rising deals
View deal benchmarks →
Gastroenterology
TL1A & microbiome deals surging
View deal benchmarks →
Hematology
CAR-T & gene therapy leaders
View deal benchmarks →